Baker Avenue Asset Management, LP Vaxcyte, Inc. Transaction History
Baker Avenue Asset Management, LP
- $3.56 Billion
- Q4 2024
A detailed history of Baker Avenue Asset Management, LP transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Baker Avenue Asset Management, LP holds 13,143 shares of PCVX stock, worth $1.03 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
13,143
Previous 13,143
-0.0%
Holding current value
$1.03 Million
Previous $1.5 Million
28.33%
% of portfolio
0.03%
Previous 0.04%
Shares
5 transactions
Others Institutions Holding PCVX
# of Institutions
349Shares Held
130MCall Options Held
539KPut Options Held
253K-
Vanguard Group Inc Valley Forge, PA12MShares$941 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X010.6MShares$832 Million0.46% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$782 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$683 Million11.52% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.21MShares$488 Million0.11% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $4.67B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...